Video Experimental Relacionado
Updated: May 7, 2026
10:37
Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
21.9K
La supresión de la trombosis arterial sin afectar los parámetros hemostáticos con una pepducina PAR1 que penetra en
Ping Zhang1, András Gruber, Shogo Kasuda
1Hemostasis & Thrombosis Laboratory, Tufts Medical Center, Box 7510, 750 Washington St, Boston, MA 02111, USA.
Circulation
|June 19, 2012
Resumen
Un nuevo inhibidor de PAR1, PZ-128, reduce efectivamente la activación plaquetaria y la trombosis durante la intervención coronaria percutánea sin afectar la hemostasis. Este nuevo terapéutico ofrece una inhibición plaquetaria rápida y reversible para los síndromes coronarios agudos.
Área de la Ciencia:
- Medicina Cardiovascular La medicina cardiovascular es una especialidad de la salud.
- Farmacología Farmacología.
- Investigación de la trombosis.
Sus antecedentes:
- La intervención coronaria percutánea (PCI) aumenta la activación plaquetaria dependiente de la trombina, aumentando el riesgo de trombosis arterial y la necrosis miocárdica en los síndromes coronarios agudos.
- Los tratamientos existentes se enfrentan a desafíos con efectos adversos, lo que pone de relieve la necesidad de nuevas terapias dirigidas a la activación plaquetaria mientras se preserva la hemostasis.
- El receptor activado por proteasa 1 (PAR1) es un mediador clave de la señalización de la trombina y un objetivo emergente para la terapia antiplaquetaria.
Objetivo del estudio:
- Desarrollar y caracterizar un inhibidor PAR1 intracelular de primera clase (PZ-128) para su uso en ICP.
- Evaluar las propiedades farmacocinéticas, la eficacia y la seguridad de PZ-128 en modelos preclínicos.
Principales métodos:
- Desarrollo de PZ-128, una pepducina que penetra en las células y se dirige a la interfaz del receptor PAR1 con la proteína G.
- Evaluación de la aparición rápida de PZ-128, supresión de la agregación plaquetaria y efectos antitrombóticos en conejillos de indias y babuinos.
- Evaluación del impacto de PZ-128 en los parámetros de sangrado y coagulación en primates y muestras de sangre humana.
Principales resultados:
- PZ-128 demostró un rápido inicio de acción, suprimiendo la agregación plaquetaria mediada por PAR1 y la trombosis arterial in vivo.
- El inhibidor mostró una fuerte sinergia con el clopidogrel y la recuperación completa de la función plaquetaria dentro de las 24 horas.
- Lo más importante es que PZ-128 no afectó los parámetros de sangrado o coagulación en primates o sangre humana, lo que indica un perfil de seguridad favorable.
Conclusiones:
- PZ-128 exhibe una potente actividad antiplaquetaria con un inicio rápido y efecto reversible, adecuado para entornos de ICP aguda.
- La falta de efectos adversos en la hemostasis sugiere que PZ-128 puede ofrecer una alternativa más segura a los inhibidores PAR1 existentes.
- PZ-128 representa un prometedor candidato terapéutico para el manejo de la activación plaquetaria en pacientes sometidos a PCI por síndromes coronarios agudos.
Más Videos Relacionados
Videos de Conceptos Relacionados
01:21Paracrine Signaling
50.3K
Paracrine signaling allows cells to communicate with their immediate neighbors via secretion of signaling molecules. Such a signal can only trigger a response in nearby target cells because the signal molecules degrade quickly or are inactivated if not taken up. Prominent examples of paracrine signaling include nitric oxide signaling in blood vessels, synaptic signaling of neurons, the blood clotting system, tissue repair/wound healing, and local allergic skin reactions. Nitric oxide as a...
50.3K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.6K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
01:16Clot Retraction and Fibrinolysis
6.1K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.1K
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
618
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
618
01:23Inhibitors of Gram-positive Cell Wall Synthesis
225
Bacterial cell walls are typically rigid structures composed mainly of peptidoglycan, a mesh-like polymer that provides mechanical strength and maintains cell shape. The synthesis of peptidoglycan is a crucial process in bacterial growth and serves as a primary target for many antibiotics.Mechanism of Action of Beta-Lactam AntibioticsBeta-lactam antibiotics, such as penicillin, inhibit peptidoglycan synthesis in actively growing cells. These antibiotics share a characteristic four-membered...
225